Senior Director, Country Manager, Switzerland

About the role

Reporting to the Vice President, General Manager, Mid-Sized Markets of Europe, the Country Manager, Switzerland will lead the expansion efforts critical to maximizing the opportunity for Revolution Medicines (RevMed) innovation to help patients. In collaboration with the regional leadership team, the successful catalytic leader will develop and execute commercial and operational strategy to accelerate the engagement with key stakeholders and customers (government authorities, regulatory authorities, payer authorities, KOLs) in Switzerland as well as all necessary constituencies to support expansion into the European region - ensuring that reimbursement and access considerations are integrated in the existing and future clinical program design of the company portfolio / pipeline. The incumbent will be responsible for developing pre-launch and commercialization strategic plans for Switzerland and providing Swiss-specific input into lifecycle plans across the RevMed portfolio. This individual will have full accountability for the Switzerland P&L, all Switzerland operations and will ensure official, fiduciary, corporate, legal and compliance requirements are met locally and for the European region respectively.

Responsibilities

• Develop and execute comprehensive plans for the company's expansion in Switzerland.
• Develop and manage the Switzerland P&L including the budget for operations, ensuring optimal resource allocation.
• As dictated by the commercialization strategy, build and lead the required multifunctional management team, working with corporate functional leaders to ensure that each team member and business function execute against the clear and well-aligned business objectives.
• Lead the planning and execution of product launches in Switzerland, including PEL, market access strategies, pricing, medical affairs atrategy, disease area and marketing strategy, and where appropriate, early access programs.
• Represent the company in Swiss healthcare policy forums and industry associations, collaborate with peers to shape collective positions and advocate for patient centered policies.
• Evaluate the competitive environment and understand the profile of portfolio compounds and the patients to serve to identify opportunities and challenges in the oncology market across Europe and other key markets.
• Set key launch and financial performance metrics including revenue, profitability etc.
• Provide Switzerland input for Mid-Sized Markets, Regional and Global Clinical Development Plans.
• Support the Clinical Operations team by ensuring appropriate Swiss site selection, quality and enrollment in-line with regulatory/compliance requirements.
• Co-lead with Finance, Legal, and Commercial, the selection and contract negotiation with any local distributor and Trade 3 rd parties and upon completion of contract, oversee and be accountable for successful execution and achievement of goals by the distributor.
• Support the effective negotiation of consultant/agency contracts for timely and cost-effective services in various business areas to support pre-launch and launch activities.
• Foster a culture within the Mid-Sized markets leadership team, regional and global team consistent with the global RevMed values and vision/mission.
• Build, lead, and develop the country organization, including medical, access, sales, marketing, and customer-facing roles as the business scales.
• Establish commercial processes, governance, and ways of working as part of the country build-out.
• Foster a culture of accountability, collaboration, and performance excellence.
• Establish country governance, risk management, and compliance framework and SOPs.
• Ensure all activities comply with local regulations, industry codes, and internal company policies.
• Required Skills, Experience and Education:
• Advanced degree

Benefits

Additional Information

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

Your Match

How well this role fits your profile.

Company Intel

What employees say

Worked at revolutionmedicines? Share your experience